We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Bellicum Pharmaceuticals Inc (BLCM) USD0.01

Sell:$1.30 Buy:$1.35 Change: $0.11 (8.92%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.30
Buy:$1.35
Change: $0.11 (8.92%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.30
Buy:$1.35
Change: $0.11 (8.92%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies for the treatment of various forms of cancer. The Company has developed CAR-T product candidates in cellular immunotherapy through which a patient’s or donor’s T cells are genetically modified to carry chimeric antigen receptors (CARs). It uses a Chemical Induction of Dimerization (CID) technology platform to engineer its product candidates with switch technologies that are designed to control components of the immune system in real time. Its product candidates include BPX-601 and BPX-603. BPX-601, is an autologous GoCAR-T product candidate containing inducible MyD88/CD40 (iMC) activation switch, designed to treat solid tumors expressing prostate stem cell antigen (PSCA). BPX-603 is its dual-switch GoCAR-T product candidate and is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen.

Contact details

Address:
2130 WEST HOLCOMBE BOULEVARD, SUITE 850
HOUSTON
77030
United States
Telephone:
+1 (832) 3841100
Website:
www.bellicum.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BLCM
ISIN:
US0794814048
Market cap:
$10.42 million
Shares in issue:
8.61 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Richard Fair
    President, Chief Executive Officer, Director
  • Charity Scripture
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.